Barclays: Maintaining a wait-and-see rating for Beam Therapeutics (BEAM.US) shares, and the target price was adjusted from $26.00 to $42.00.
巴克莱：维持Beam Therapeutics(BEAM.US)持股观望评级，目标价由26.00美元调整至42.00美元。
Barclays: Maintaining a wait-and-see rating for Beam Therapeutics (BEAM.US) shares, and the target price was adjusted from $26.00 to $42.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.